Oral Peptides & Macrocyclics Icon

Cambridge Healthtech Institute’s 12th Annual

Oral Peptides & Macrocyclics

bRo5 Yet Drug-Like Molecules

APRIL 3 - 4, 2024


Cambridge Healthtech Institute's Oral Peptides & Macrocyclics conference continues its focus on how to discover or design beyond rule-of-five (bRo5) molecules with oral bioavailability potential: larger molecules better suited for protein-protein interaction (PPI) drug targets than typical small molecule drug candidates, yet able to penetrate cells and reach the intracellular PPI targets that are often disease culprits. This year, however, more emphasis will be placed on the emergence of oral peptides, which are usually macrocyclic or constrained, and how they are expanding the chemical space available to medicinal, computational, and synthetic chemists for finding molecules that can bind larger surfaces with more stability. Join colleagues to learn more about designing or screening newer "large small molecule" drug modalities.

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director and Lead Content Director for Drug Discovery Chemistry

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com


For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431

Email: kskahan@healthtech.com